Sign In
Buy NTRA
$318.35
-3.75 (-1.16%)
At Close: Aug 10, 2026
SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery
06:00am, Tuesday, 31'st Mar 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a publication in Clinical Cancer Research showing that Signatera w
3,400 Shares in Natera, Inc. $NTRA Purchased by Connective Portfolio Management LLC
04:45am, Thursday, 26'th Mar 2026
Connective Portfolio Management LLC bought a new stake in shares of Natera, Inc. (NASDAQ: NTRA) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities a
Natera Looks Compelling As Oncology Testing Momentum Keeps Building
11:51am, Tuesday, 17'th Mar 2026
NTRA's oncology franchise, led by Signatera MRD testing, is the main bull case at this point. As long as they keep building on their testing volumes, I believe this should support a long runway in can
Bamco Inc. NY Trims Stock Position in Natera, Inc. $NTRA
04:08am, Tuesday, 17'th Mar 2026
Bamco Inc. NY lessened its stake in Natera, Inc. (NASDAQ: NTRA) by 53.3% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The f
NTRA Debuts Zenith Genomics Next-Gen Sequencing Test for Rare Diseases
10:42am, Monday, 16'th Mar 2026
Natera launches Zenith genomics whole-genome sequencing assay with MyOme to boost rare disease detection and expand diagnostics reach across the United States.
Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers
06:00am, Monday, 16'th Mar 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced two peer-reviewed publications highlighting the clinical utility o
Natera, Inc. $NTRA Position Reduced by Bank of Hawaii
03:07am, Saturday, 14'th Mar 2026
Bank of Hawaii reduced its stake in shares of Natera, Inc. (NASDAQ: NTRA) by 18.6% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Com
Invesco Main Street Mid Cap Fund Q4 2025 Portfolio Activity
12:49pm, Thursday, 12'th Mar 2026
We maintain our valuation discipline and our focus on companies with competitive advantages and skilled management teams that we believe are executing better than their peers. We initiated a position
Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis
08:00am, Thursday, 12'th Mar 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the commercial launch of Zenith genomics, its next-generation whol
MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026
08:00am, Thursday, 12'th Mar 2026
MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- MyOme, a leader in clinical whole-genome analysis, announced an advancement in rare disease diagnostics at the American College of Medical Genetics
Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript
01:52am, Thursday, 12'th Mar 2026
Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Focus Partners Advisor Solutions LLC Has $1.70 Million Stake in Natera, Inc. $NTRA
04:00am, Friday, 06'th Mar 2026
Focus Partners Advisor Solutions LLC grew its stake in Natera, Inc. (NASDAQ: NTRA) by 72.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (S
Natera, Inc. (NTRA) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
01:52am, Thursday, 05'th Mar 2026
Natera, Inc. (NTRA) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Natera, Inc. (NTRA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
12:42pm, Wednesday, 04'th Mar 2026
Natera, Inc. (NTRA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation
10:05am, Friday, 27'th Feb 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced it will present new data in genitourinary malignancies at the Amer
